Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
Authors Esteban Jódar-Gimeno
Published Date May 2007 Volume 2007:2(1) Pages 163—174
Published 16 May 2007
Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain
Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.
Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.
Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.
Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.
Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.
Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)
Readers of this article also read:
Neurophysiological correlates of response inhibition predict relapse in detoxified alcoholic patients: some preliminary evidence from event-related potentials
Petit G, Cimochowska A, Kornreich C, Hanak C, Verbanck P, Campanella S
Published Date: 9 June 2014
Published Date: 14 May 2014
Esposito M, Roccella M, Gallai B, Parisi L, Lavano SM, Marotta R, Carotenuto M
Published Date: 11 September 2013
Occult nonmetallic intraocular foreign bodies presenting as fulminant uveitis: a case series and review of the literature
Sychev YV, Verner-Cole EA, Suhler EB, Stout JT, Vemulakonda GA
Published Date: 2 September 2013
Using poly(lactic-co-glycolic acid) microspheres to encapsulate plasmid of bone morphogenetic protein 2/polyethylenimine nanoparticles to promote bone formation in vitro and in vivo
Qiao C, Zhang K, Jin H, Miao L, Shi C, Liu X, Yuan A, Liu J, Li D, Zheng C, Zhang G, Li X, Yang B, Sun H
Published Date: 13 August 2013
Qu X, Yao C, Wang J, Li Z, Zhang Z
Published Date: 26 April 2013
Vardharajula S, Ali SZ, Tiwari PM, Eroğlu E, Vig K, Dennis VA, Singh SR
Published Date: 9 October 2012
Cárdenas WH, Mamani JB, Sibov TT, Caous CA, Amaro E Jr, Gamarra LF
Published Date: 21 September 2012
Published Date: 13 July 2012
Shuster JE, Bleske BE, Dorsch MP
Published Date: 13 June 2012